Business Wire

The Estée Lauder Companies Launches 2022 Breast Cancer Campaign to Honor 30 th Anniversary and Positively Impact the Global Breast Cancer Community

Share

In the 30 years since Evelyn H. Lauder launched The Estée Lauder Companies’ Breast Cancer Campaign (The Campaign) and co-created the Pink Ribbon in 1992, The Campaign’s mission to help create a breast cancer-free world for all has remained steadfast. The Estée Lauder Companies (ELC) has a long-standing commitment to helping women and girls achieve their highest potential. As ELC’s largest corporate social impact program, The Campaign is a cornerstone of ELC’s social investments in women’s advancement and health, uniting people everywhere to positively impact the global breast cancer community. As breast cancer is the most commonly diagnosed cancer in the world,1 ELC's continued commitment to improving the lives of all those touched by the disease remains unwavering.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220930005040/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

The Estée Lauder Companies Launches 2022 Breast Cancer Campaign (Graphic: Business Wire)

Together, The Estée Lauder Companies’ Breast Cancer Campaign and The Estée Lauder Companies Charitable Foundation (ELCCF) have funded more than $108 million globally for lifesaving research, education and medical services, with more than $86 million funding medical research grants through the Breast Cancer Research Foundation (BCRF). Founded in 1993 by Evelyn H. Lauder, BCRF is dedicated to advancing the world’s most promising research. ELC’s commitment to breast cancer research, spanning three decades, has been transformative. In partnership with BCRF, The Campaign has helped fuel research across the entire spectrum of the disease—from tumor biology, lifestyle and genetics, survivorship, treatment, and metastasis—making an indelible mark in the diagnosis, care, and prevention of breast cancer. In addition, The Campaign supports more than 60 organizations worldwide, facilitating real change aligned to the diverse needs of local communities.

Deaths from breast cancer have declined 42% in the U.S. since the late 1980s.2 However, that progress has not been experienced equally and certain populations are at higher risk for adverse breast cancer outcomes. At every age, Black women in the U.S. are more likely to die from breast cancer than any other race or ethnic group, and mortality rates remain 41% higher than in white women, despite lower incidence.3 The Campaign has and continues to support BCRF-funded research that identifies and addresses disparities that exist across the entire breast cancer landscape. ELCCF’s $15 million donation over five years will fund a new BCRF research initiative to accelerate The Campaign’s goal of reducing breast cancer disparities and improving outcomes. This comprehensive study of the intersection of social determinants of health, comorbidities, and the biology of breast cancer in Black women has the potential to significantly impact breast cancer disparities globally. It will help advance personalized breast cancer health care across prevention, diagnosis, and treatment for those at most risk of dying from the disease, and has the potential to be groundbreaking for the global breast cancer community.

William P. Lauder, Executive Chairman of The Estée Lauder Companies Inc. shared, “The potential impact that this BCRF initiative will have in accelerating a crucial area of research cannot be overstated, as we collectively work towards a more equitable future for all. I know my mother, Evelyn Lauder, would be so proud of the advancements we have made through research, education, access to care and our commitment to help end breast cancer.”

In the past 30 years globally, The Campaign has:

  • Funded medical research and fellowships, as well as medical resources, services and centers, including access to mammograms and screenings for vulnerable groups with limited access to healthcare.
  • Advanced conversations on the importance of breast health education and early detection by facilitating discussions between the breast cancer community, medical experts and key opinion leaders.
  • Supported therapy and counseling programs to help improve the lives of people with breast cancer and their families.
  • Distributed educational materials and more than 180 million Pink Ribbons to spread awareness.

“The Estée Lauder Companies’ success is deeply rooted in living our shared values. Reflecting on the last 30 years, the incredible progress made by The Breast Cancer Campaign has had a lasting impact on our global community. As an authentic cornerstone of our commitments, The Campaign has been supported by our employees, consumers and partners worldwide. Today, it continues to inspire action in people everywhere. As a Beauty Inspired, Values Driven company, we look forward to the future and are committed to advancing positive change for all of those touched by this disease,” said Fabrizio Freda, President and Chief Executive Officer, The Estée Lauder Companies Inc.

The Campaign will take the following actions aligned to its mission for its 30th Anniversary:

  • Double-down on The Campaign’s efforts to reduce breast cancer disparities and improve health outcomes.
  • Mobilize ELC’s passionate employees to unite in action and support more than 60 organizations worldwide.
  • Show support through 18 of ELC’s brands: Estée Lauder, Clinique, Lab Series, Origins, La Mer, Bobbi Brown, Aveda, Jo Malone London, Bumble and bumble, Darphin Paris, TOM FORD BEAUTY, Smashbox, AERIN Beauty, Editions de Parfums Frédéric Malle, GLAMGLOW, KILIAN PARIS, Too Faced, and Dr.Jart+. Each will donate to BCRF and/or local cancer-focused organizations around the world, with brand participation varying by market.
  • Convene breast cancer thought leaders and advocates to advance education and share important messages about the disease.
  • Drive additional donations to BCRF through ELCompanies.com/BreastCancerCampaign and various points of engagement.
  • Accelerate communications on social media including TikTok and various Meta platforms to foster awareness, fundraising and engagement, including new calls-to-action.
  • Unveil a new series of global stories demonstrating the diversity of the disease.
  • Continue The Campaign’s tradition of illuminating buildings, monuments and landmarks around the world in glowing pink lights to raise awareness of breast health, including the Empire State Building, New York City; the Eiffel Tower, Paris; LOTTE WORLD TOWER, Seoul.
  • Continue producing and distributing informative materials and Pink Ribbons worldwide.

As long as breast cancer remains a life-threatening disease, The Estée Lauder Companies’ commitment to the meaningful work that must continue will not waiver. It’s #TimeToEndBreastCancer.

ABOUT THE ESTÉE LAUDER COMPANIES INC.
The Estée Lauder Companies Inc. is one of the world’s leading manufacturers, marketers, and sellers of quality skin care, makeup, fragrance, and hair care products. The company’s products are sold in approximately 150 countries and territories under brand names including: Estée Lauder, Aramis, Clinique, Lab Series, Origins, M·A·C, La Mer, Bobbi Brown, Aveda, Jo Malone London, Bumble and bumble, Darphin Paris, TOM FORD BEAUTY, Smashbox, AERIN Beauty, Le Labo, Editions de Parfums Frédéric Malle, GLAMGLOW, KILIAN PARIS, Too Faced, Dr.Jart+, and the DECIEM family of brands, including The Ordinary and NIOD.

ELC-C
ELC-I

_____________________________
1 World Health Organization
2 American Cancer Society® Facts and Figures 2021-2022
3 American Cancer Society® Key Statistics for Breast Cancer

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Erin Cohen
The Estée Lauder Companies
ercohen@estee.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Datopotamab Deruxtecan Showed Promising Responses as Monotherapy and in Combination with Durvalumab in Patients with Metastatic Triple Negative Breast Cancer in Two Early Trials9.12.2022 14:00:00 CET | Press release

Updated results from the TROPION-PanTumor01 phase 1 trial showed datopotamab deruxtecan (Dato-DXd) continued to demonstrate encouraging responses in patients with heavily pretreated metastatic triple negative breast cancer (TNBC) and disease progression following standard treatment. Results were presented today as a poster presentation (Abstract #P6-10-03) at the 2022 San Antonio Breast Cancer Symposium (#SABCS22). Datopotamab deruxtecan is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) being jointly developed by Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: AZN). Approximately 15% of breast cancers are considered triple negative and are associated with higher disease recurrence and worse prognosis compared to other breast cancer subtypes.1,2 It is estimated that only 12% of patients with metastatic TNBC survive five years after diagnosis and median overall survival is between 12 to 18 months.1,3 In the TNBC cohort of TROPION-PanTumor01 (n=44)

Takeda to Present Data at 64th American Society of Hematology (ASH) Annual Meeting, Demonstrating Commitment to Patients with Hematologic Cancers and Other Blood Diseases9.12.2022 14:00:00 CET | Press release

Takeda(TSE:4502/NYSE:TAK) today announced that it will present 15 company-sponsored abstracts at the 64th American Society of Hematology (ASH) Annual Meeting being held December 10-13, 2022 in New Orleans. Takeda’s latest research focuses on improving long-term outcomes for patients with hematologic diseases. Takeda’s presentations will include oral sessions detailing a three-year update of the Phase 3 OPTIC trial demonstrating the efficacy and safety of ICLUSIG® (ponatinib) in patients with resistant chronic-phase chronic myeloid leukemia (CP-CML), and results from a first-in-human Phase 1/2 study evaluating modakafusp alfa (TAK-573) in patients with relapsed / refractory multiple myeloma. “Our latest research is focused on investigating novel mechanisms of action, as well as optimizing approved treatments to improve long-term outcomes and more deeply understand and address unmet needs for patients across a range of hematologic diseases,” said Awny Farajallah, M.D., Head of Global Med

Tecnotree Advances to Acquire Top AIML Platform - CognitiveScale in North America to further Enhance 5G Use case Penetration9.12.2022 13:23:00 CET | Press release

Tecnotree is a market leader in 5G digital Business Support Systems (BSS), with AI/ML capabilities and multi-cloud extensibility. Tecnotree’s global footprint with over 90 Telecom customers in 70 countries around the world, supports ecosystems of over 1 billion subscribers. Tecnotree is the first Digital Platform Service provider to be Platinum Badge Certified by TM Forum for Real-world Open API standards. The company also provides B2B2X partner ecosystem and fintech services for monetization beyond connectivity across gaming, healthcare, education, and banking. Tecnotree has been recognized by Gartner for revenue management and monetization as well as for customer experience management solutions and enjoys the position of a leading stock on the Helsinki Nasdaq since 2020. CognitiveScale (CS) is United States based pioneer in the space of AI Engineering and provides solutions for scalable enterprise AI development and deployment. CognitiveScale is backed by over 100 granted AI patents

Another Sustainability Award for NTHU9.12.2022 10:00:00 CET | Press release

National Tsing Hua University (NTHU) in Taiwan has been awarded the Taiwan University Sustainability Award for the second year in a row! The Award was announced at the 15th Taiwan Corporate Sustainability Awards (TCSA) recently held by the Taiwan Institute for Sustainable Energy (TAISE). Standing out amongst the 47 participating universities, NTHU was ranked first in the comprehensive evaluation, and in the individual competitions received the University Sustainability Report Gold Award. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221209005001/en/ NTHU president W. John Kao (right) accepting the Taiwan University Sustainability Award from You Si-kun, president of the Legislative Yuan. (Photo: National Tsing Hua University) The judges cited the exemplary way in which NTHU has adopted an innovative approach to integrating classroom learning, campus activities and social service, thereby enriching students’ education and cre

Carbios Hosts World’s First PET Biorecycling Summit with Bertrand Piccard, Initiator and Chairman of the Solar Impulse Foundation, as Keynote Speaker9.12.2022 06:45:00 CET | Press release

Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221208005776/en/ Bertrand Piccard, Initiator and Chairman of the Solar Impulse Foundation, as Keynote Speaker at the First World PET Biorecycling Summit organised by Carbios Carbios (Euronext Growth Paris: ALCRB), a pioneer in the development and industrialization of biological technologies to reinvent the life cycle of plastics and textiles, hosted the world’s first PET Biorecycling Summit from 7 to 8 December 2022 in Paris. The event attracted over 100 international participants from the scientific, academic, and industrial worlds to exchange on the advances in the field of biological recycling, and how to bring these innovations for a circular economy to market. The two-day conference gathered world-renowned scientists from various academic institutions to share their latest research on PET enzymatic depolymerization. Bertrand Piccard, Initiator and Chairman

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom